CD40 and neoplasm: There are different approaches targeting TAMs as to limit monocyte recruitment into tumor tissues by CCL2-blocking agent [61], to inhibit the activation of TAMs by CSF1/CSF1R inhibitors [62], reprogramm TAMs into antitumor macrophages using CD40 agonist [63] or IL-10 mAbs [64], and deplete macrophages by clodronate-liposome [65].